Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/52008
DC FieldValueLanguage
dc.contributor.authorWägner, Ana María-
dc.contributor.authorSánchez-Quesada, Jose Luis-
dc.contributor.authorBenítez, Sonia-
dc.contributor.authorBancells, Cristina-
dc.contributor.authorOrdóñez-Llanos, Jordi-
dc.contributor.authorPérez, Antonio-
dc.date.accessioned2018-11-25T16:40:02Z-
dc.date.available2018-11-25T16:40:02Z-
dc.date.issued2011-
dc.identifier.issn0168-8227-
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/52008-
dc.description.abstractA randomized, crossover study compared the effects of atorvastatin, gemfibrozil and their combination on inflammatory markers in type 2 diabetes. C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), secretory phospholipase A2 (sPLA2), interleukin 8 (IL8), monocyte chemotactic protein 1 (MCP1) and tumor necrosis factor alpha (TNF alpha) were measured. Both lipid-lowering drugs had positive, complementary and additive effects on inflammatory markers, which were closely related to baseline inflammatory status.-
dc.languageeng-
dc.publisher0168-8227-
dc.relation.ispartofDiabetes Research and Clinical Practice-
dc.sourceDiabetes Research and Clinical Practice [ISSN 0168-8227], v. 93 (1), p. E25-E28, (Julio 2011)-
dc.subject320502 Endocrinología-
dc.subject.otherAtorvastatin-
dc.subject.otherGemfibrozil-
dc.subject.otherInflammation Markers-
dc.subject.otherC-Reactive Protein-
dc.subject.otherPhospholipase A2-
dc.titleEffect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study-
dc.typeinfo:eu-repo/semantics/Article-
dc.typeArticle-
dc.identifier.doi10.1016/j.diabres.2011.03.009-
dc.identifier.scopus79960556707-
dc.identifier.isi000293008400011-
dc.contributor.authorscopusid7401456520-
dc.contributor.authorscopusid6603877734-
dc.contributor.authorscopusid6701865216-
dc.contributor.authorscopusid6506892110-
dc.contributor.authorscopusid7005297613-
dc.contributor.authorscopusid7402509742-
dc.description.lastpageE28-
dc.identifier.issue1-
dc.description.firstpageE25-
dc.relation.volume93-
dc.investigacionCiencias de la Salud-
dc.type2Artículo-
dc.contributor.daisngid450201-
dc.contributor.daisngid478642-
dc.contributor.daisngid607980-
dc.contributor.daisngid1832495-
dc.contributor.daisngid136499-
dc.contributor.daisngid754556-
dc.description.numberofpages4-
dc.utils.revision-
dc.contributor.wosstandardWOS:Wagner, AM-
dc.contributor.wosstandardWOS:Sanchez-Quesada, JL-
dc.contributor.wosstandardWOS:Benitez, S-
dc.contributor.wosstandardWOS:Bancells, C-
dc.contributor.wosstandardWOS:Ordonez-Llanos, J-
dc.contributor.wosstandardWOS:Perez, A-
dc.date.coverdateJulio 2011-
dc.identifier.ulpgc-
dc.description.sjr0,96
dc.description.jcr2,754
dc.description.sjrqQ1
dc.description.jcrqQ2
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptDiabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-7663-9308-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameWägner, Anna Maria Claudia-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

13
checked on Jun 13, 2021

WEB OF SCIENCETM
Citations

11
checked on Jun 13, 2021

Page view(s)

25
checked on Jun 13, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.